[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551075":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":12,"centralContacts":32,"locations":42,"responsibleParty":85,"collaborators":89,"id":100,"slug":12,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":12,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":12,"enrollmentInfo":108,"targetDuration":12,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":45,"whyStopped":12,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University Hospital of North Norway","OTHER",[8,13,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","Current clinical practise. Levothyroxine dose is calculated based on weight and adjusted according to TSH-level at 6-8 week intervals until biochemical target is reached",null,{"label":14,"type":15,"description":16,"interventionNames":17},"DST 1","EXPERIMENTAL","Levothyroxine dose is calculated using the current version of the decision support tool based on 4 blood samples.",[18],"Other: Decision support tool",{"label":20,"type":15,"description":21,"interventionNames":22},"DST 2","Levothyroxine dose is calculated using an improved mathematical model in the decision support tool based on 4 blood samples.",[18],{"label":24,"type":15,"description":25,"interventionNames":26},"DST 3","Levothyroxine dose is calculated using an improved mathematical model in the decision support tool based on 2 blood samples.",[18],[28],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":12},"Decision support tool","Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.",[14,20,24],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":12,"email":37},"Vegard Brun, PhD","CONTACT","0047 77669260","vegard.heimly.brun@unn.no",{"name":39,"role":35,"phone":40,"phoneExt":12,"email":41},"Solveig Brun, cand.med","004745253006","solveig.konst@unn.no",[43,60,73],{"facility":44,"status":45,"city":46,"state":12,"zip":12,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Haukeland University Hospital","RECRUITING","Bergen","Norway","NO",{"type":50,"coordinates":51},"Point",[52,53],5.32415,60.39299,{"lat":53,"lon":52},[56],{"name":57,"role":35,"phone":58,"phoneExt":12,"email":59},"Renate Kollevåg Vik, PhD","+4795210732","Renate.Cecilie.Kollevag.Vik@helse-bergen.no",{"facility":61,"status":45,"city":62,"state":12,"zip":12,"country":47,"countryCode":48,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Oslo University Hospital","Oslo",{"type":50,"coordinates":64},[65,66],10.74609,59.91273,{"lat":66,"lon":65},[69],{"name":70,"role":35,"phone":71,"phoneExt":12,"email":72},"Ingrid Alm Andersen, PhD","+47 91 50 27 70","aningr@ous-hf.no",{"facility":5,"status":45,"city":74,"state":12,"zip":75,"country":47,"countryCode":48,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Tromsø","9010",{"type":50,"coordinates":77},[78,79],18.95508,69.6489,{"lat":79,"lon":78},[82],{"name":83,"role":35,"phone":84,"phoneExt":12,"email":41},"Solveig Konst, Cand.Med","+4777754259",{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Vegard Brun","Consultant physician and associate professor",[90,92,95,97],{"name":91,"class":6},"SINTEF Health Research",{"name":93,"class":94},"Helseapps","UNKNOWN",{"name":96,"class":94},"Norinnova",{"name":98,"class":99},"Helse Nord","INDUSTRY","100551075",false,"NCT06455371","Patient-centered Dosage of Levothyroxine","Patient-centered Decision Support Tool for Levothyroxine Dosage","Inclusion Criteria:\n\n* Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals\n\nExclusion Criteria:\n\n* Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy","ALL","18 Years",{"count":109,"type":110},240,"ESTIMATED","INTERVENTIONAL",[113],"NA","Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.",[116,117,118],"Hypothyroidism","Thyroid Cancer","Thyroid",[29,120,121,122],"Patient-centered dosage","thyroidectomy","levothyroxine","2025-09-03",{"date":125,"type":126},"2025-09-10","ACTUAL",{"date":128,"type":126},"2024-12-20",{"date":130,"type":110},"2027-12",{"name":5,"class":6},3]